Last $9.22 USD
Change Today -0.54 / -5.53%
Volume 22.1K
AKAO On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 5:10 PM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).

achaogen inc (AKAO) Snapshot

Open
$9.74
Previous Close
$9.76
Day High
$10.00
Day Low
$9.18
52 Week High
03/24/14 - $19.69
52 Week Low
09/29/14 - $7.72
Market Cap
163.7M
Average Volume 10 Days
12.1K
EPS TTM
$-1.34
Shares Outstanding
17.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACHAOGEN INC (AKAO)

Related News

No related news articles were found.

achaogen inc (AKAO) Related Businessweek News

No Related Businessweek News Found

achaogen inc (AKAO) Details

Achaogen, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections. The company is principally developing plazomicin, which has completed Phase II clinical trials for the treatment of bacterial infections due to multi-drug resistant Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. It is also involved in the research and development of antipseudomonal programs that target infections caused by Pseudomonas aeruginosa. Achaogen, Inc. was incorporated in 2002 and is headquartered in South San Francisco, California.

43 Employees
Last Reported Date: 11/10/14
Founded in 2002

achaogen inc (AKAO) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $367.2K
Vice President of Finance and Corporate Devel...
Total Annual Compensation: $248.1K
Vice President of Regulatory Affairs
Total Annual Compensation: $279.8K
Compensation as of Fiscal Year 2013.

achaogen inc (AKAO) Key Developments

Achaogen, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Achaogen, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported contract revenue of USD 4.520 million compared to USD 4.289 million a year ago. Loss from operations was USD 8.333 million compared to USD 2.295 million a year ago. Net loss was USD 8.312 million compared to USD 2.563 million a year ago. Basic and diluted loss per common share was USD 0.47 compared to USD 6.52 a year ago. For the nine months, the company reported contract revenue of USD 15.711 million compared to USD 12.320 million a year ago. Loss from operations was USD 14.905 million compared to USD 9.783 million a year ago. Net loss was USD 15.322 million compared to USD 10.626 million a year ago. Basic and diluted loss per common share was USD 1.18 compared to USD 27.55 a year ago.

Achaogen, Inc. Presents at Credit Suisse Annual Healthcare Conference, Nov-11-2014 03:30 PM

Achaogen, Inc. Presents at Credit Suisse Annual Healthcare Conference, Nov-11-2014 03:30 PM. Venue: The Biltmore, 2400 E Missouri Ave, Phoenix, AZ 85016, United States. Speakers: Kenneth J. Hillan, Chief Executive Officer and Director.

Achaogen, Inc. Announces the Resignation of Becki Filice as Senior Vice President, Development Operations and Portfolio Management, Effective November 4, 2014

On October 8, 2014, Becki Filice, Senior Vice President, Development Operations and Portfolio Management of Achaogen, Inc. notified the company of her resignation from her position with the company effective November 4, 2014 for personal reasons.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKAO:US $9.22 USD -0.54

AKAO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AKAO.
View Industry Companies
 

Industry Analysis

AKAO

Industry Average

Valuation AKAO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.9x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACHAOGEN INC, please visit www.achaogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.